Literature DB >> 12947001

Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2.

Barbara Margosio1, Daniela Marchetti, Veronica Vergani, Raffaella Giavazzi, Marco Rusnati, Marco Presta, Giulia Taraboletti.   

Abstract

The antiangiogenic factor thrombospondin 1 (TSP-1) binds with high affinity to several heparin-binding angiogenic factors, including fibroblast growth factor 2 (FGF-2), vascular endothelial growth factor (VEGF), and hepatocyte growth factor/scatter factor (HGF/SF). The aim of this study was to investigate whether TSP-1 affects FGF-2 association with the extracellular matrix (ECM) and its bioavailability. TSP-1 prevented the binding of free FGF-2 to endothelial cell ECM. It also promoted the mobilization of matrix-bound FGF-2, generating a TSP-1/FGF-2 complex. The region of TSP-1 responsible for these activities was located within the 140-kDa antiangiogenic and FGF-2 binding fragment, whereas the 25-kDa heparin-binding fragment was inactive. Matrix-released FGF-2/TSP-1 complex had a reduced ability to bind to and induce proliferation of endothelial cells. TSP-1 depleted the ECM laid by FGF-2-overproducing tumor cells of its FGF-2-dependent mitogenic activity for endothelial cells. Besides FGF-2, TSP-1 also inhibited VEGF and HGF/SF binding to the ECM and mobilized them from the ECM. Our study shows that TSP-1 acts as a scavenger for matrix-associated angiogenic factors, affecting their location, bioavailability, and function.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12947001     DOI: 10.1182/blood-2003-03-0893

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  32 in total

1.  Pregnancy-associated genes contribute to antiluteolytic mechanisms in ovine corpus luteum.

Authors:  Jared J Romero; Alfredo Q Antoniazzi; Natalia P Smirnova; Brett T Webb; Fang Yu; John S Davis; Thomas R Hansen
Journal:  Physiol Genomics       Date:  2013-09-17       Impact factor: 3.107

2.  Vascular growth factor binding kinetics to the endothelial cell basement membrane, with a kinetics-based correction for substrate binding.

Authors:  Alisa Morss Clyne; Elazer R Edelman
Journal:  Cytotechnology       Date:  2009-07-29       Impact factor: 2.058

Review 3.  Angiogenesis.

Authors:  Donald R Senger; George E Davis
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-08-01       Impact factor: 10.005

4.  Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domain.

Authors:  Barbara Margosio; Marco Rusnati; Katiuscia Bonezzi; Blue-Leaf A Cordes; Douglas S Annis; Chiara Urbinati; Raffaella Giavazzi; Marco Presta; Domenico Ribatti; Deane F Mosher; Giulia Taraboletti
Journal:  Int J Biochem Cell Biol       Date:  2007-10-09       Impact factor: 5.085

Review 5.  Regulation of thrombospondin1 by extracellular proteases.

Authors:  M Luisa Iruela-Arispe
Journal:  Curr Drug Targets       Date:  2008-10       Impact factor: 3.465

Review 6.  Thrombospondin and apoptosis: molecular mechanisms and use for design of complementation treatments.

Authors:  Y Mirochnik; A Kwiatek; O V Volpert
Journal:  Curr Drug Targets       Date:  2008-10       Impact factor: 3.465

7.  Non-peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: an integrated strategy for the development of new antiangiogenic compounds.

Authors:  Giorgio Colombo; Barbara Margosio; Laura Ragona; Marco Neves; Silvia Bonifacio; Douglas S Annis; Matteo Stravalaci; Simona Tomaselli; Raffaella Giavazzi; Marco Rusnati; Marco Presta; Lucia Zetta; Deane F Mosher; Domenico Ribatti; Marco Gobbi; Giulia Taraboletti
Journal:  J Biol Chem       Date:  2010-01-07       Impact factor: 5.157

8.  Interaction of NG2(+) glial progenitors and microglia/macrophages from the injured spinal cord.

Authors:  Junfang Wu; Soonmoon Yoo; Donna Wilcock; Judith M Lytle; Philberta Y Leung; Carol A Colton; Jean R Wrathall
Journal:  Glia       Date:  2010-03       Impact factor: 7.452

9.  Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors.

Authors:  Anders Olsson; Anders Björk; Johan Vallon-Christersson; John T Isaacs; Tomas Leanderson
Journal:  Mol Cancer       Date:  2010-05-17       Impact factor: 27.401

10.  Thrombospondins function as regulators of angiogenesis.

Authors:  Paul Bornstein
Journal:  J Cell Commun Signal       Date:  2009-10-02       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.